NYMX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 liep. 2023 @ 23:00):

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally...

Stats
Šios dienos apimtis	881 574
Vidutinė apimtis	134 777
Rinkos kapitalizacija	18.24M
EPS	$0.0100 ( 2023-08-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.161 (16.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2022-05-02	Robinson James George	Buy	1 151 515	Warrant
2021-04-22	Robinson James George	Buy	200	Common Stock

INSIDER POWER
100.00
Last 100 transactions
Buy: 1 546 252 \| Sell: 0

Tūris Koreliacija

Ilgas: -0.08 (neutral)

Trumpas: -0.02 (neutral)

Signal:(67.127) Neutral

Nymox Pharmaceutical Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Nymox Pharmaceutical Corp Koreliacija - Valiuta/Žaliavos

-0.25
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.59
( weak negative )

-0.04
( neutral )

0.38
( neutral )

Nymox Pharmaceutical Corp Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.0735

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.0735

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.150

FY	2020
Pajamos:	$5 000.00
Bruto pelnas:	$1 000.00 (20.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.